Urine Metabolite Profiling for Differentiating LUTS Causes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical urinalysis methods fail to differentiate between healthy and incontinent subjects and do not provide adequate data to understand the underlying causes of lower urinary tract symptoms like overactive bladder and urinary urge incontinence, limiting effective prognosis and treatment.
Innovation Solution
A method of detecting specific metabolites such as ascorbate, dehydroascorbate, CEHC-sulfate, and others in urine samples to produce metabolic profiles that characterize and differentiate lower urinary tract symptoms, using techniques like LC-MS/MS and NMR for analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If typical clinical urinalysis is performed, then the testing process is simple and quick, but it fails to differentiate between healthy and incontinent subjects and does not provide adequate data to understand underlying causes
Solution Approach 1:
The patent segments the complex metabolic analysis into detection of multiple individual metabolites (ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucuronide, and others). Each metabolite serves as a specific diagnostic marker that, when analyzed collectively, provides comprehensive differentiation capability for LUTS conditions while maintaining a structured, manageable approach to the overall diagnostic process
Solution Approach 2:
The metabolic profile analysis system serves multiple diagnostic functions simultaneously: it differentiates between healthy and incontinent subjects, identifies underlying causes of LUTS, provides prognosis information, and characterizes specific conditions like overactive bladder and urinary urge incontinence. This multi-functionality resolves the contradiction by making the complex system worthwhile through its comprehensive diagnostic capabilities
2Reliability
If metabolic analysis with multiple metabolite detection is performed, then diagnostic accuracy and underlying mechanism understanding improve, but the complexity and cost of testing increase
Solution Approach 1:
The patent establishes a comprehensive metabolic profile framework in advance, identifying specific metabolites (ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucuronide, pantoate, 5-aminovalerate, galactonate, phenylacetylalanine, and others) that are relevant to LUTS diagnosis. This preliminary identification of target metabolites allows the complex system to be structured and prepared beforehand, making the actual diagnostic process more manageable and reliable
Solution Approach 2:
The patent changes the diagnostic parameters from traditional urinalysis measurements to specific metabolite concentrations and ratios. By monitoring changes in multiple metabolite parameters simultaneously, the system achieves high reliability in prognosis and differentiation, transforming the complex problem into a multi-parameter measurement approach that provides robust diagnostic information
3Loss of information
If traditional urinalysis is used, then the testing procedure is straightforward, but it cannot provide metabolic profiles that characterize lower urinary tract symptoms
Solution Approach 1:
The patent introduces metabolic profiling as an intermediary layer between traditional urinalysis and comprehensive diagnostic understanding. By detecting specific metabolites that serve as intermediaries in bladder function and LUTS pathophysiology, the system bridges the gap between simple urine collection and complex mechanism understanding, preserving ease of sample collection while adding valuable metabolic information
Solution Approach 2:
The patent creates a metabolic profile copy or representation of the complex bladder physiological state through measurement of multiple urine metabolites. This metabolic fingerprint serves as a simplified representation that captures essential diagnostic information about LUTS conditions, making complex physiological information accessible through a relatively simple testing procedure
Data Source
AI summary
Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.